In a notable advancement in the oncology sector, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a globally recognized oncology company, has received approval from the U.S. Food and Drug Administration (FDA) for TEVIMBRA (tislelizumab-jsgr). This approval marks a significant milestone for TEVIMBRA as a monotherapy in the treatment of adult patients with unresectable or […]
AstraZeneca has reached a crucial milestone as the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Imfinzi (durvalumab) for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC). This recommendation paves the way for a new treatment option for […]
